Who is on it, and how far along Every drug ChEMBL records acting on PTGIR, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Treprostinil Treprostinil SponsorUnited Therapeutics ModalitySmall molecule ActionAgonist Open trials36 Epoprostenol Epoprostenol SponsorGSK ModalitySmall molecule ActionAgonist Open trials31 Selexipag Selexipag SponsorJohnson & Johnson ModalitySmall molecule ActionAgonist Open trials11 Iloprost Iloprost SponsorJohnson & Johnson ModalitySmall molecule ActionAgonist Open trials10 Phase 32 Ralinepag Ralinepag SponsorUnited Therapeutics ModalitySmall molecule ActionAgonist Open trials1 Esuberaprost Esuberaprost SponsorLung Biotechnology PBC ModalitySmall molecule ActionAgonist Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Prostanoid IP receptor agonist. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 25 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Local Iloprost Therapy to Promote Bone Healing in High Risk Fractures Iloprost Phase 2 Not yet recruiting Charite University, Berlin, Germany Nov 9, 2026 Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) Treprostinil Phase 2 Not yet recruiting United Therapeutics Nov 6, 2026 An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) Treprostinil Phase 2 / Phase 3 Not yet recruiting United Therapeutics Nov 6, 2026 Colchicine in Pulmonary Artery Hypertension Patients Epoprostenol Phase 2 Not yet recruiting Ain Shams University Oct 30, 2026 PACE: Prostacyclin AntiCoagulation in ECMO Epoprostenol Phase 1 / Phase 2 Not yet recruiting Garrett Keim Sep 24, 2026 Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH) Treprostinil Early phase 1 Recruiting Valley Health System Sep 24, 2026 A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF) Treprostinil Phase 3 Recruiting Insmed Incorporated Sep 4, 2026 A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag Epoprostenol, Selexipag, Treprostinil Phase 4 Recruiting Liquidia Technologies, Inc. Aug 12, 2026 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks Epoprostenol, Treprostinil Phase 2 Not yet recruiting Liquidia Technologies, Inc. Aug 5, 2026 TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends Treprostinil — Not yet recruiting AOP Orphan Pharmaceuticals AG Jul 30, 2026 Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension Epoprostenol, Iloprost, Selexipag Phase 4 Recruiting University of Sao Paulo General Hospital Jul 20, 2026 Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO) Epoprostenol, Selexipag Not applicable Not yet recruiting University of Alberta Jul 14, 2026 A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment Treprostinil Phase 1 Recruiting Insmed Incorporated Jun 11, 2026 A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) Epoprostenol Phase 4 Recruiting Merck Sharp & Dohme LLC May 22, 2026 Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease Iloprost Phase 3 Not yet recruiting University Hospital, Rouen Mar 27, 2026 AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? Iloprost Not applicable Recruiting University of Sao Paulo General Hospital Mar 9, 2026 Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial Hypertension Epoprostenol, Selexipag — Not yet recruiting Caio Júlio César dos Santos Fernandes Mar 5, 2026 Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude Iloprost — Not yet recruiting Institute of Mountain Emergency Medicine Mar 4, 2026 Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO) Iloprost Phase 4 Not yet recruiting University of Colorado, Denver Feb 20, 2026 Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension Iloprost, Selexipag — Not yet recruiting University of Sao Paulo General Hospital Jan 21, 2026 Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD) Iloprost Not applicable Not yet recruiting University of Sao Paulo General Hospital Dec 4, 2025 Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study Selexipag — Recruiting Qianfoshan Hospital Dec 31, 2024 Pulmonary Hypertension: Intensification and Personalisation of Combination Rx Selexipag Phase 4 Active, not recruiting Sheffield Teaching Hospitals NHS Foundation Trust Apr 24, 2023 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Selexipag Phase 3 Recruiting Actelion Jan 5, 2022 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Ralinepag Phase 3 Enrolling by invitation United Therapeutics Sep 25, 2018
Show all 25Diseases most associated with it Open Targets association score, 0 to 1; all associations Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1995 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. Gene name, function (UniProt P43119 , CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets